Skip to content

Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias

Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04078685
Acronym
COBRA-PATH
Enrollment
113
Registered
2019-09-06
Start date
2018-06-12
Completion date
2021-03-20
Last updated
2020-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tachycardia; Paroxysmal, Supraventricular, Tachycardia, Supraventricular

Brief summary

The aim of this single-center prospective randomized controlled trial is to assess the superiority of contact-force-(CF)-sensing-based approach compared to conventional (non-CF-sensing) approach in the catheter ablation of PSVTs, and to investigate the safety of open-irrigated, contact-force-sensing ablation catheters (used in a non-irrigated mode) in these procedures.

Detailed description

Rationale: Multiple studies have demonstrated the importance of adequate catheter-tissue contact in the creation of effective lesions during radiofrequency catheter ablation. The development of contact-force(CF)-sensing catheters have contributed significantly to improve clinical outcomes in atrial fibrillation 3-18. However CF-sensing technology is not used in the ablation of paroxysmal supraventricular tachycardia. Although PSVT ablation with the conventional approach (non-irrigated, non-CF-sensing catheters) is considered a relatively low-risk procedure with fairly high success rate (short-and long-term) 1,2,19, we hypothesize that contact-force sensing can further improve the outcomes of these procedures. Based on the results of studies on atrial fibrillation ablation (mentioned above) we believe that CF-sensing could similarly improve such important parameters as radiofrequency (RF) application number/time, total procedure time, and fluoroscopy time in cases of PSVT ablations, as well. In addition CF-sensing could also further improve acute success/recurrence rates of PSVT ablation, and might also be capable to further diminish complication risk. Primary Objective: The primary objective of the present study is to demonstrate the superiority of contact-force-sensing in the ablation of AVNRT and WPW-AVRT as assessed by the improvement in the number and duration of radiofrequency applications compared with the conventional ablation approach. Secondary Objective: Secondary objectives of the study are the followings: * to demonstrate that contact-force-sensing catheters are superior in terms of total procedure duration and fluoroscopy times in the case of AVNRT/WPW-AVRT ablation. * to show that the use of contact-force sensing catheters is non-inferior to conventional catheters (without contact-force-sensing) in terms of acute/long-term procedural success and procedural safety (major/minor complication rate) of AVNRT/WPW-AVRT ablations. Study population: All patients above 18 years without structural heart disease being referred for electrophysiological study and potential treatment with radiofrequency catheter ablation of atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT) with manifest (WPW syndrome) or concealed accessory pathways. Intervention: One group undergoes manual ablation using standard non-irrigated ablation catheters and the other group undergoes manual ablation with an open-irrigated ablation catheter equipped with CF- sensing (and utilized in a non-irrigated mode during ablation) Main study parameters/endpoints: The main study endpoint is the difference in RF application number during the procedures of AVNRT/WPW-AVRT ablation; secondary endpoints are differences in RF application rate, acute success rate, long-term recurrence rate (1 year) major/minor complication rate, and total procedure/fluoroscopy time.

Interventions

PROCEDUREStandard catheter ablation

Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing

PROCEDUREContact Force-sensing-based catheter ablation

Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter

Sponsors

Erasmus Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Referral for electrophysiology study because of pre-excitation on 12-lead surface ECG and/or documented (or suspected) symptomatic PSVT * Identification of AVNRT or WPW-AVRT (with manifest or concealed accessory pathway) during standard EP study * Verbal consent to continue with ablation therapy * Informed written consent to be included in the study

Exclusion criteria

* evidence of structural heart disease and/or myocardial ischemia * pregnancy (and lack of exclusion of potential pregnancy) * age below 18 years

Design outcomes

Primary

MeasureTime frameDescription
Number of radiofrequency applicationsFrom the beginning till the end of the ablation procedureThe number of radiofrequency applications during the ablation procedures of AVNRT and WPW-AVRT

Secondary

MeasureTime frameDescription
Overall duration of radiofrequency applicationsFrom the beginning till the end of the ablation proceduretotal of time spend from the beginning till the end of the ablation procedure
Long-term procedural successAt 12 monthsFree from recurrence of pre-excitation or the same clinical type of paroxysmal supraventricular tachycardia (AVNRT or AVRT)
Acute procedural success/failureat the end of the ablation procedurenon-inducibility of clinical arrhythmia verified at the end of the standard EP study
Time to recurrence of AVNRT/WPW-AVRTup till 12 monthsif recurrence of AVNRT/WPW-AVRT, time to recurrence
Total duration of procedureFrom the beginning till the end of the ablation proceduretotal time for duration of the procedure
(Serious) Adverse EventsTill 12 monthsall reported SAEs
Fluoroscopy timeFrom the beginning till the end of the ablation proceduretotal time for fluoroscopy time

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026